|
|
Post by kc on Apr 26, 2017 13:47:15 GMT -5
Seems a CTO order has been filed with the SEC in addition Amphstar has one filed today at the same time too.
www.sec.gov/Archives/edgar/data/899460/999999999717005733/filename1.pdf
Strange that they both filed in the middle of the trading day. Maybe it means nothing or maybe some kind of news at 4:00PM eastern time when the market closes. Its been a very long and downward ride into the Abyss. Maybe our day is coming SHORTLY for better or worse we are prepared for whatever happens.
Since the reaction by the ticker is going down today it must not be positive for the shareholder unless MannKind has a can of whoop ass up their sleeve. |
|
|
|
Post by sla55 on Apr 26, 2017 13:49:36 GMT -5
|
|
|
|
Post by factspls88 on Apr 26, 2017 13:51:52 GMT -5
More uncertainty - just what we need. Let's hope it's for a positive reason.
|
|
|
|
Post by Jstokcton on Apr 26, 2017 13:57:22 GMT -5
COULD IT BE: ir.amphastar.com/releasedetail.cfm?releaseid=1005509Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene® Mist The new Primatene® Mist is made with the same active ingredient, epinephrine, that was used in the original Primatene® Mist. However, the product's new inhalation delivery system no longer includes chlorofluorocarbons (CFCs), which were phased out of various products worldwide as part of an international environmental treaty. Primatene® Mist also includes other important new features, including a built-in spray indicator and a pressurized metal canister that replaces the glass container used in the original Primatene® Mist product. Amphastar partners/buys with MNKD for EPI? |
|
|
|
Post by jlaw277 on Apr 26, 2017 13:59:25 GMT -5
Here's the link to Ex-10.33 in the 10K link |
|
|
|
Post by sla55 on Apr 26, 2017 14:03:22 GMT -5
|
|
|
|
Post by jred on Apr 26, 2017 14:07:11 GMT -5
Exhibit 10.33 in the 10K is related to the amended supply agreement with Amphastar. It appears that Mannkind filed to keep the schedule of purchase commitments confidential. It covers the quantity and price per gram from 2014 through 2023.
|
|
|
|
Post by peppy on Apr 26, 2017 14:13:55 GMT -5
Exhibit 10.33 in the 10K is related to the amended supply agreement with Amphastar. It appears that Mannkind filed to keep the schedule of purchase commitments confidential. It covers the quantity and price per gram from 2014 through 2023. jred, you have been such a huge asset to longs. Thank you. |
|
|
|
Post by jred on Apr 26, 2017 14:29:03 GMT -5
Thank you, but I have learned far more from this site than I could ever provide back.
|
|
|
|
Post by otherottawaguy on Apr 26, 2017 14:29:55 GMT -5
I still get uppity when I see CTO, I still think it means "Cease Trade Order" and not the actual meaning "Confidential Treatment Request"
OOG
|
|
|
|
Post by kbrion77 on Apr 26, 2017 14:34:04 GMT -5
How many pages will this get up to? Mannkind can't pay its bills to both Deerfield and Amphastar. I see this is already wasting space on StockTwits on speculation.
|
|
|
|
Post by mnholdem on Apr 26, 2017 14:51:26 GMT -5
This is just an observation of mine, but the agreement specifies that the [***] (undisclosed) payment for insulin required to be purchased from Amphistar in 2017 is due November 5, 2017 which is well after the scheduled PDUFA date for the FDA Afrezza label change. Beginning 2018, insulin payments are once again scheduled to be paid quarterly.
|
|
|
|
Post by therealisaching on Apr 26, 2017 14:54:37 GMT -5
This is just an observation of mine, but the agreement specifies that the [***] (undisclosed) payment for insulin required to be purchased from Amphistar in 2017 is due November 5, 2017 which is well after the scheduled PDUFA date for the FDA Afrezza label change. Beginning 2018, insulin payments are once again scheduled to be paid quarterly.
From memory, I believe that structure was in place when they made the amendment last year |
|
|
|
Post by derek2 on Apr 26, 2017 14:54:48 GMT -5
What a great example of a high quality thread! Initial document followed by members posting fact-based details from the 10-K without a hint of tin foil. Compare that to the craziness on Stock Twits...
|
|
|
|
Post by matt on Apr 26, 2017 15:03:55 GMT -5
CTO treatment is routine any time pricing data is disclosed that one or both parties don't want in the public domain. Imagine how easy it would be for the next Amphastar customer to look up the pricing that Mannkind obtained and used that as a negotiation tool to get a better price. CTO treatments are also common in royalty and milestone agreements for the same reason. Nothing sinister here, just normal business practice.
|
|
